Stay updated on Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe record’s latest update dates changed from July 30–31, 2026, to November 11–12, 2026.SummaryDifference0.1%

- Check9 days agoChange DetectedThe NIH transition announcement about updated terminology and related FAQs was removed from the top of the page.SummaryDifference1%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0. The study record page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces updates to NIH websites and says some NIH content may use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) during the transition.SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision changed from v3.7.1 to v3.7.2; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page remains a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tazemetostat + Pembrolizumab in Urothelial Carcinoma Clinical Trial page.